Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin’s lymphoma

Targeted radioimmunotherapy in non-Hodgkin’s B-cell lymphoma (NHL) offers an efficacious therapy and minimal toxicity compared to conventional chemotherapy. Iodine 131 tositumomab ((131)I-TST) is a murine monoclonal antibody against the CD20 cell surface protein and is directly covalently conjugated...

Descripción completa

Detalles Bibliográficos
Autores principales: Burdick, Michael J, Macklis, Roger M
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886324/
https://www.ncbi.nlm.nih.gov/pubmed/20616910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886324/
https://www.ncbi.nlm.nih.gov/pubmed/20616910

Ejemplares similares